Another Metabolic one:Aldehydes
@j Checkpoint blockade works in tumours types with mismatch DNA repair defects https://www.science.org/content/article/cancer-immunotherapy-takes-aim-mutation-riddled-tumors
However, most patients don't have such defects. So, one group decided to test temozolomide, which disables mismatch repair genes, to a number of patients with advanced MSS CRC, which usually doesn't respond to checkpoint inhibitor therapy, due to very few mutations. Now, the clinical data from the trial shows proof-of-concept https://ascopubs.org/doi/full/10.1200/JCO.21.02583
Also, unpublished preclinical data showed that adding cisplatin with temozolomide had a synergistic effect and a trial is recruiting https://clinicaltrials.gov/ct2/show/NCT04457284
In addition, one company is working on first-in-class small molecules https://www.neophore.com
critic thank you for replying.
My New Year's Resolution is to get back to the forum. I'll start the New Year off right with a post.
I have been wondering about 3-BP's effectiveness in the BRAF resistant form of melanoma; below article found that melanoma in this context is highly metabolic and 3-BP had substantial anti-cancer effects.
I am very excited to see what 2023 will offer us. Finally having the needed clinical evidence for 3-BP could help so many people struggling with metastatic illness.
Best Wishes for 2023!
@jcancom that's a great new year's resolution, J! I always think in terms of combinations, and Rapamycin seems like a good substance to try with 3BP, likely resulting in a reduced dose requirement of 3BP to achieve similar effects.
Best wishes for 2023!
Best wishes for 2023, guys!
Here it is everyone !!! Yeah! We have waited so long for this! This could help millions and millions of cancer patients! It appears that they want to move this through trials post haste.
This is the google translation of the website:
"KAT has entered the U.S. Food and Drug Administration's Phase 1/2a clinical trial." Pharma first received US FDA (Food and Drug Administration) Phase 1/2a IND (clinical trial plan) approval for liver cancer last year," he explained.
... "In Korea, after the IRB (Clinical Research Review Board) review, we started recruiting patients in August of this year. "Phase 1 clinical trial will take about 1 year and 6 months, and the goal is to finish it by the end of 2023."
It's NewG Lab Pharma doing the 3BP trial, right? Looking at the company's stock price things are not going well.
Do you have any news?